“…However, the PTM pattern of CHO cells is not identical to human PTMs (Dumont et al, 2016) and the incompatibility with some types of proteins negatively affects drug efficacy, potency or stability (Goh and Ng, 2017;Kuriakose et al, 2016). Therefore, besides further development of the CHO cell-line to meet the high-quality PTM requirements and increased yields (Datta et al, 2013;Fouladiha et al, 2020;Koffas et al, 2018;Liang et al, 2020;Tejwani et al, 2018;Wang et al, 2020), a lot of focus on improving hosts for biopharmaceutical production is on cell factories derived from human cells with the natural ability of generating human PTMs, such as the Human Embryonic Kidney 293 HEK293cells (Almo and Love, 2014;Malm et al, 2020;Tegel et al, 2020).…”